The global Age-related Macular Degeneration market was valued at US$ 7725.7 million in 2023 and is anticipated to reach US$ 11400 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.

Age-related Macular Degeneration Market

North American market for Age-related Macular Degeneration is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Age-related Macular Degeneration is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Age-related Macular Degeneration in Drugstore is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Age-related Macular Degeneration include Bayer HealthCare, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, Alcon, Allergan, Avalanche, Bausch+Lomb and Gilead Sciences, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Age-related Macular Degeneration, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Age-related Macular Degeneration.

Report Scope

The Age-related Macular Degeneration market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Age-related Macular Degeneration market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Age-related Macular Degeneration companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Age-related Macular Degeneration Market Report

Report Metric	Details
Report Name	Age-related Macular Degeneration Market
Accounted market size in 2023	US$ 7725.7 million
Forecasted market size in 2030	US$ 11400 million
CAGR	5.8%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Wet AMD Dry AMD
Segment by Application	Drugstore Hospital Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Bayer HealthCare, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, Alcon, Allergan, Avalanche, Bausch+Lomb, Gilead Sciences, Iconic Therapeutics, Neurotech Pharmaceuticals, Ohr Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Age-related Macular Degeneration companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Age-related Macular Degeneration Market growing?

Ans: The Age-related Macular Degeneration Market witnessing a CAGR of 5.8% during the forecast period 2024-2030.

What is the Age-related Macular Degeneration Market size in 2030?

Ans: The Age-related Macular Degeneration Market size in 2030 will be US$ 11400 million.

Who are the main players in the Age-related Macular Degeneration Market report?

Ans: The main players in the Age-related Macular Degeneration Market are Bayer HealthCare, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, Alcon, Allergan, Avalanche, Bausch+Lomb, Gilead Sciences, Iconic Therapeutics, Neurotech Pharmaceuticals, Ohr Pharmaceutical

What are the Application segmentation covered in the Age-related Macular Degeneration Market report?

Ans: The Applications covered in the Age-related Macular Degeneration Market report are Drugstore, Hospital, Others

What are the Type segmentation covered in the Age-related Macular Degeneration Market report?

Ans: The Types covered in the Age-related Macular Degeneration Market report are Wet AMD, Dry AMD

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Age-related Macular Degeneration Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Wet AMD

1.2.3 Dry AMD

1.3 Market by Application

1.3.1 Global Age-related Macular Degeneration Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Drugstore

1.3.3 Hospital

1.3.4 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Age-related Macular Degeneration Market Perspective (2019-2030)

2.2 Age-related Macular Degeneration Growth Trends by Region

2.2.1 Global Age-related Macular Degeneration Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Age-related Macular Degeneration Historic Market Size by Region (2019-2024)

2.2.3 Age-related Macular Degeneration Forecasted Market Size by Region (2025-2030)

2.3 Age-related Macular Degeneration Market Dynamics

2.3.1 Age-related Macular Degeneration Industry Trends

2.3.2 Age-related Macular Degeneration Market Drivers

2.3.3 Age-related Macular Degeneration Market Challenges

2.3.4 Age-related Macular Degeneration Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Age-related Macular Degeneration Players by Revenue

3.1.1 Global Top Age-related Macular Degeneration Players by Revenue (2019-2024)

3.1.2 Global Age-related Macular Degeneration Revenue Market Share by Players (2019-2024)

3.2 Global Age-related Macular Degeneration Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Age-related Macular Degeneration Revenue

3.4 Global Age-related Macular Degeneration Market Concentration Ratio

3.4.1 Global Age-related Macular Degeneration Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Age-related Macular Degeneration Revenue in 2023

3.5 Age-related Macular Degeneration Key Players Head office and Area Served

3.6 Key Players Age-related Macular Degeneration Product Solution and Service

3.7 Date of Enter into Age-related Macular Degeneration Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Age-related Macular Degeneration Breakdown Data by Type

4.1 Global Age-related Macular Degeneration Historic Market Size by Type (2019-2024)

4.2 Global Age-related Macular Degeneration Forecasted Market Size by Type (2025-2030)

5 Age-related Macular Degeneration Breakdown Data by Application

5.1 Global Age-related Macular Degeneration Historic Market Size by Application (2019-2024)

5.2 Global Age-related Macular Degeneration Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Age-related Macular Degeneration Market Size (2019-2030)

6.2 North America Age-related Macular Degeneration Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Age-related Macular Degeneration Market Size by Country (2019-2024)

6.4 North America Age-related Macular Degeneration Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Age-related Macular Degeneration Market Size (2019-2030)

7.2 Europe Age-related Macular Degeneration Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Age-related Macular Degeneration Market Size by Country (2019-2024)

7.4 Europe Age-related Macular Degeneration Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Age-related Macular Degeneration Market Size (2019-2030)

8.2 Asia-Pacific Age-related Macular Degeneration Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Age-related Macular Degeneration Market Size by Region (2019-2024)

8.4 Asia-Pacific Age-related Macular Degeneration Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Age-related Macular Degeneration Market Size (2019-2030)

9.2 Latin America Age-related Macular Degeneration Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Age-related Macular Degeneration Market Size by Country (2019-2024)

9.4 Latin America Age-related Macular Degeneration Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Age-related Macular Degeneration Market Size (2019-2030)

10.2 Middle East & Africa Age-related Macular Degeneration Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Age-related Macular Degeneration Market Size by Country (2019-2024)

10.4 Middle East & Africa Age-related Macular Degeneration Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Bayer HealthCare

11.1.1 Bayer HealthCare Company Detail

11.1.2 Bayer HealthCare Business Overview

11.1.3 Bayer HealthCare Age-related Macular Degeneration Introduction

11.1.4 Bayer HealthCare Revenue in Age-related Macular Degeneration Business (2019-2024)

11.1.5 Bayer HealthCare Recent Development

11.2 F. Hoffmann-La Roche

11.2.1 F. Hoffmann-La Roche Company Detail

11.2.2 F. Hoffmann-La Roche Business Overview

11.2.3 F. Hoffmann-La Roche Age-related Macular Degeneration Introduction

11.2.4 F. Hoffmann-La Roche Revenue in Age-related Macular Degeneration Business (2019-2024)

11.2.5 F. Hoffmann-La Roche Recent Development

11.3 Novartis

11.3.1 Novartis Company Detail

11.3.2 Novartis Business Overview

11.3.3 Novartis Age-related Macular Degeneration Introduction

11.3.4 Novartis Revenue in Age-related Macular Degeneration Business (2019-2024)

11.3.5 Novartis Recent Development

11.4 Regeneron Pharmaceuticals

11.4.1 Regeneron Pharmaceuticals Company Detail

11.4.2 Regeneron Pharmaceuticals Business Overview

11.4.3 Regeneron Pharmaceuticals Age-related Macular Degeneration Introduction

11.4.4 Regeneron Pharmaceuticals Revenue in Age-related Macular Degeneration Business (2019-2024)

11.4.5 Regeneron Pharmaceuticals Recent Development

11.5 Alcon

11.5.1 Alcon Company Detail

11.5.2 Alcon Business Overview

11.5.3 Alcon Age-related Macular Degeneration Introduction

11.5.4 Alcon Revenue in Age-related Macular Degeneration Business (2019-2024)

11.5.5 Alcon Recent Development

11.6 Allergan

11.6.1 Allergan Company Detail

11.6.2 Allergan Business Overview

11.6.3 Allergan Age-related Macular Degeneration Introduction

11.6.4 Allergan Revenue in Age-related Macular Degeneration Business (2019-2024)

11.6.5 Allergan Recent Development

11.7 Avalanche

11.7.1 Avalanche Company Detail

11.7.2 Avalanche Business Overview

11.7.3 Avalanche Age-related Macular Degeneration Introduction

11.7.4 Avalanche Revenue in Age-related Macular Degeneration Business (2019-2024)

11.7.5 Avalanche Recent Development

11.8 Bausch+Lomb

11.8.1 Bausch+Lomb Company Detail

11.8.2 Bausch+Lomb Business Overview

11.8.3 Bausch+Lomb Age-related Macular Degeneration Introduction

11.8.4 Bausch+Lomb Revenue in Age-related Macular Degeneration Business (2019-2024)

11.8.5 Bausch+Lomb Recent Development

11.9 Gilead Sciences

11.9.1 Gilead Sciences Company Detail

11.9.2 Gilead Sciences Business Overview

11.9.3 Gilead Sciences Age-related Macular Degeneration Introduction

11.9.4 Gilead Sciences Revenue in Age-related Macular Degeneration Business (2019-2024)

11.9.5 Gilead Sciences Recent Development

11.10 Iconic Therapeutics

11.10.1 Iconic Therapeutics Company Detail

11.10.2 Iconic Therapeutics Business Overview

11.10.3 Iconic Therapeutics Age-related Macular Degeneration Introduction

11.10.4 Iconic Therapeutics Revenue in Age-related Macular Degeneration Business (2019-2024)

11.10.5 Iconic Therapeutics Recent Development

11.11 Neurotech Pharmaceuticals

11.11.1 Neurotech Pharmaceuticals Company Detail

11.11.2 Neurotech Pharmaceuticals Business Overview

11.11.3 Neurotech Pharmaceuticals Age-related Macular Degeneration Introduction

11.11.4 Neurotech Pharmaceuticals Revenue in Age-related Macular Degeneration Business (2019-2024)

11.11.5 Neurotech Pharmaceuticals Recent Development

11.12 Ohr Pharmaceutical

11.12.1 Ohr Pharmaceutical Company Detail

11.12.2 Ohr Pharmaceutical Business Overview

11.12.3 Ohr Pharmaceutical Age-related Macular Degeneration Introduction

11.12.4 Ohr Pharmaceutical Revenue in Age-related Macular Degeneration Business (2019-2024)

11.12.5 Ohr Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Bayer HealthCare

F.Hoffmann-La Roche

Novartis

Regeneron Pharmaceuticals

Neurotech Pharmaceuticals

Ohr Pharmaceutical

List of Tables

Table 1. Global Age-related Macular Degeneration Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Wet AMD

Table 3. Key Players of Dry AMD

Table 4. Global Age-related Macular Degeneration Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global Age-related Macular Degeneration Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Age-related Macular Degeneration Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global Age-related Macular Degeneration Market Share by Region (2019-2024)

Table 8. Global Age-related Macular Degeneration Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global Age-related Macular Degeneration Market Share by Region (2025-2030)

Table 10. Age-related Macular Degeneration Market Trends

Table 11. Age-related Macular Degeneration Market Drivers

Table 12. Age-related Macular Degeneration Market Challenges

Table 13. Age-related Macular Degeneration Market Restraints

Table 14. Global Age-related Macular Degeneration Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global Age-related Macular Degeneration Market Share by Players (2019-2024)

Table 16. Global Top Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-related Macular Degeneration as of 2023)

Table 17. Ranking of Global Top Age-related Macular Degeneration Companies by Revenue (US$ Million) in 2023

Table 18. Global 5 Largest Players Market Share by Age-related Macular Degeneration Revenue (CR5 and HHI) & (2019-2024)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Age-related Macular Degeneration Product Solution and Service

Table 21. Date of Enter into Age-related Macular Degeneration Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Age-related Macular Degeneration Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global Age-related Macular Degeneration Revenue Market Share by Type (2019-2024)

Table 25. Global Age-related Macular Degeneration Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global Age-related Macular Degeneration Revenue Market Share by Type (2025-2030)

Table 27. Global Age-related Macular Degeneration Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global Age-related Macular Degeneration Revenue Market Share by Application (2019-2024)

Table 29. Global Age-related Macular Degeneration Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global Age-related Macular Degeneration Revenue Market Share by Application (2025-2030)

Table 31. North America Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 32. North America Age-related Macular Degeneration Market Size by Country (2019-2024) & (US$ Million)

Table 33. North America Age-related Macular Degeneration Market Size by Country (2025-2030) & (US$ Million)

Table 34. Europe Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. Europe Age-related Macular Degeneration Market Size by Country (2019-2024) & (US$ Million)

Table 36. Europe Age-related Macular Degeneration Market Size by Country (2025-2030) & (US$ Million)

Table 37. Asia-Pacific Age-related Macular Degeneration Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 38. Asia-Pacific Age-related Macular Degeneration Market Size by Region (2019-2024) & (US$ Million)

Table 39. Asia-Pacific Age-related Macular Degeneration Market Size by Region (2025-2030) & (US$ Million)

Table 40. Latin America Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. Latin America Age-related Macular Degeneration Market Size by Country (2019-2024) & (US$ Million)

Table 42. Latin America Age-related Macular Degeneration Market Size by Country (2025-2030) & (US$ Million)

Table 43. Middle East & Africa Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Middle East & Africa Age-related Macular Degeneration Market Size by Country (2019-2024) & (US$ Million)

Table 45. Middle East & Africa Age-related Macular Degeneration Market Size by Country (2025-2030) & (US$ Million)

Table 46. Bayer HealthCare Company Detail

Table 47. Bayer HealthCare Business Overview

Table 48. Bayer HealthCare Age-related Macular Degeneration Product

Table 49. Bayer HealthCare Revenue in Age-related Macular Degeneration Business (2019-2024) & (US$ Million)

Table 50. Bayer HealthCare Recent Development

Table 51. F. Hoffmann-La Roche Company Detail

Table 52. F. Hoffmann-La Roche Business Overview

Table 53. F. Hoffmann-La Roche Age-related Macular Degeneration Product

Table 54. F. Hoffmann-La Roche Revenue in Age-related Macular Degeneration Business (2019-2024) & (US$ Million)

Table 55. F. Hoffmann-La Roche Recent Development

Table 56. Novartis Company Detail

Table 57. Novartis Business Overview

Table 58. Novartis Age-related Macular Degeneration Product

Table 59. Novartis Revenue in Age-related Macular Degeneration Business (2019-2024) & (US$ Million)

Table 60. Novartis Recent Development

Table 61. Regeneron Pharmaceuticals Company Detail

Table 62. Regeneron Pharmaceuticals Business Overview

Table 63. Regeneron Pharmaceuticals Age-related Macular Degeneration Product

Table 64. Regeneron Pharmaceuticals Revenue in Age-related Macular Degeneration Business (2019-2024) & (US$ Million)

Table 65. Regeneron Pharmaceuticals Recent Development

Table 66. Alcon Company Detail

Table 67. Alcon Business Overview

Table 68. Alcon Age-related Macular Degeneration Product

Table 69. Alcon Revenue in Age-related Macular Degeneration Business (2019-2024) & (US$ Million)

Table 70. Alcon Recent Development

Table 71. Allergan Company Detail

Table 72. Allergan Business Overview

Table 73. Allergan Age-related Macular Degeneration Product

Table 74. Allergan Revenue in Age-related Macular Degeneration Business (2019-2024) & (US$ Million)

Table 75. Allergan Recent Development

Table 76. Avalanche Company Detail

Table 77. Avalanche Business Overview

Table 78. Avalanche Age-related Macular Degeneration Product

Table 79. Avalanche Revenue in Age-related Macular Degeneration Business (2019-2024) & (US$ Million)

Table 80. Avalanche Recent Development

Table 81. Bausch+Lomb Company Detail

Table 82. Bausch+Lomb Business Overview

Table 83. Bausch+Lomb Age-related Macular Degeneration Product

Table 84. Bausch+Lomb Revenue in Age-related Macular Degeneration Business (2019-2024) & (US$ Million)

Table 85. Bausch+Lomb Recent Development

Table 86. Gilead Sciences Company Detail

Table 87. Gilead Sciences Business Overview

Table 88. Gilead Sciences Age-related Macular Degeneration Product

Table 89. Gilead Sciences Revenue in Age-related Macular Degeneration Business (2019-2024) & (US$ Million)

Table 90. Gilead Sciences Recent Development

Table 91. Iconic Therapeutics Company Detail

Table 92. Iconic Therapeutics Business Overview

Table 93. Iconic Therapeutics Age-related Macular Degeneration Product

Table 94. Iconic Therapeutics Revenue in Age-related Macular Degeneration Business (2019-2024) & (US$ Million)

Table 95. Iconic Therapeutics Recent Development

Table 96. Neurotech Pharmaceuticals Company Detail

Table 97. Neurotech Pharmaceuticals Business Overview

Table 98. Neurotech Pharmaceuticals Age-related Macular Degeneration Product

Table 99. Neurotech Pharmaceuticals Revenue in Age-related Macular Degeneration Business (2019-2024) & (US$ Million)

Table 100. Neurotech Pharmaceuticals Recent Development

Table 101. Ohr Pharmaceutical Company Detail

Table 102. Ohr Pharmaceutical Business Overview

Table 103. Ohr Pharmaceutical Age-related Macular Degeneration Product

Table 104. Ohr Pharmaceutical Revenue in Age-related Macular Degeneration Business (2019-2024) & (US$ Million)

Table 105. Ohr Pharmaceutical Recent Development

Table 106. Research Programs/Design for This Report

Table 107. Key Data Information from Secondary Sources

Table 108. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Age-related Macular Degeneration Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Age-related Macular Degeneration Market Share by Type: 2023 VS 2030

Figure 3. Wet AMD Features

Figure 4. Dry AMD Features

Figure 5. Global Age-related Macular Degeneration Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 6. Global Age-related Macular Degeneration Market Share by Application: 2023 VS 2030

Figure 7. Drugstore Case Studies

Figure 8. Hospital Case Studies

Figure 9. Others Case Studies

Figure 10. Age-related Macular Degeneration Report Years Considered

Figure 11. Global Age-related Macular Degeneration Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 12. Global Age-related Macular Degeneration Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Age-related Macular Degeneration Market Share by Region: 2023 VS 2030

Figure 14. Global Age-related Macular Degeneration Market Share by Players in 2023

Figure 15. Global Top Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-related Macular Degeneration as of 2023)

Figure 16. The Top 10 and 5 Players Market Share by Age-related Macular Degeneration Revenue in 2023

Figure 17. North America Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 18. North America Age-related Macular Degeneration Market Share by Country (2019-2030)

Figure 19. United States Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. Canada Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Europe Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe Age-related Macular Degeneration Market Share by Country (2019-2030)

Figure 23. Germany Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. France Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. U.K. Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Italy Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Russia Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Nordic Countries Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Asia-Pacific Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific Age-related Macular Degeneration Market Share by Region (2019-2030)

Figure 31. China Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Japan Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. South Korea Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Southeast Asia Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. India Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Australia Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Latin America Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America Age-related Macular Degeneration Market Share by Country (2019-2030)

Figure 39. Mexico Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Brazil Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Middle East & Africa Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa Age-related Macular Degeneration Market Share by Country (2019-2030)

Figure 43. Turkey Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Saudi Arabia Age-related Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Bayer HealthCare Revenue Growth Rate in Age-related Macular Degeneration Business (2019-2024)

Figure 46. F. Hoffmann-La Roche Revenue Growth Rate in Age-related Macular Degeneration Business (2019-2024)

Figure 47. Novartis Revenue Growth Rate in Age-related Macular Degeneration Business (2019-2024)

Figure 48. Regeneron Pharmaceuticals Revenue Growth Rate in Age-related Macular Degeneration Business (2019-2024)

Figure 49. Alcon Revenue Growth Rate in Age-related Macular Degeneration Business (2019-2024)

Figure 50. Allergan Revenue Growth Rate in Age-related Macular Degeneration Business (2019-2024)

Figure 51. Avalanche Revenue Growth Rate in Age-related Macular Degeneration Business (2019-2024)

Figure 52. Bausch+Lomb Revenue Growth Rate in Age-related Macular Degeneration Business (2019-2024)

Figure 53. Gilead Sciences Revenue Growth Rate in Age-related Macular Degeneration Business (2019-2024)

Figure 54. Iconic Therapeutics Revenue Growth Rate in Age-related Macular Degeneration Business (2019-2024)

Figure 55. Neurotech Pharmaceuticals Revenue Growth Rate in Age-related Macular Degeneration Business (2019-2024)

Figure 56. Ohr Pharmaceutical Revenue Growth Rate in Age-related Macular Degeneration Business (2019-2024)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

Figure 59. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions